Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 6/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8909117 | 1.00 | ADORA1 (0.68) | ADORA1ADORA3ADORA2AHTR2C | |
| SCHEMBL9404414 | 1.00 | ADORA1 (0.68) | ADORA1ADORA3ADORA2AHTR2C | |
| SCHEMBL8910560 | 1.00 | ADORA1 (0.68) | ADORA1ADORA3ADORA2AHTR2C | |
| SCHEMBL3847109 | 1.00 | ADORA1 (0.68) | ADORA1ADORA3ADORA2AHTR2C | |
| SCHEMBL8910803 | 1.00 | ADORA1 (0.68) | ADORA1ADORA3ADORA2AHTR2C | |
| SCHEMBL9404332 | 0.92 | ADORA1 (0.66) | ADORA1ADORA3ADORA2AHTR2C | |
| SCHEMBL8909940 | 0.92 | ADORA1 (0.61) | ADORA1ADORA3ADORA2AHTR2C | |
| SCHEMBL9404329 | 0.92 | ADORA1 (0.66) | ADORA1ADORA3ADORA2AHTR2C | |
| SCHEMBL9404281 | 0.92 | ADORA1 (0.61) | ADORA1ADORA3ADORA2AHTR2C | |
| SCHEMBL8909046 | 0.91 | ADORA3 (0.62) | ADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5672588-A | Purine derivatives | NOVO NORDISK A/S (DK) | 1997-09-30 | — | — | US | claimed |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-19 | — | — | US | disclosed |
| US-5672588-A | Purine derivatives | NOVO NORDISK A/S (DK) | 1997-09-30 | — | — | US | disclosed |
| EP-0603348-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993023418-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADORA2A, PDE4A, PDE4D | ADORA1 31/4885ADORA3 27/4885ADORA2A 1/4885 |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | BCL6, BCL6B, BCL3 | ADORA1 83/4885ADORA3 101/4885ADORA2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.